The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …

Observational studies have determined hyperphosphatemia to be a cardiovascular risk
factor in chronic kidney disease. Mechanistic studies have elucidated that …

Disturbances in mineral and bone metabolism are common in patients with CKD. A large
body of evidence indicates that these derangements are associated with increased mortality …

We recently identified a novel gene, termed klotho (kl) that is involved in the development of
a syndrome in mice resembling human aging. A defect of the kl gene expression in mice …

Renal osteodystrophy, the term used to describe the skeletal complications of end-stage
renal disease, is a multifactorial disorder of bone remodeling. The actions of some of the …

PTH is a major systemic regulator of the concentrations of calcium, phosphate, and active
vitamin D metabolites in blood and of cellular activity in bone. Intermittently administered …

Secondary hyperparathyroidism (SHPT) affects a majority of patients with chronic kidney
disease (CKD) of stage 3 or worse. Despite the development of calcimimetics and their …

We developed a novel immunoradiometric assay (IRMA; whole parathyroid hormone [PTH]
IRMA) for PTH, which specifically measures biologically active whole PTH (1–84). The assay …

Control of serum phosphate without any phosphate binders in patients treated with nocturnal
hemodialysis. We compared the efficacy and the long-term effects of nocturnal hemodialysis …

The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI)
suggested that intact parathyroid hormone (iPTH) should be maintained in a target range …